Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer

Observational cohort study

Juan P. Wisnivesky, Cardinale B. Smith, Stuart Packer, Gary M. Strauss, Linda Lurslurchachai, Alex Federman, Ethan A. Halm

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Objective: To compare the survival and risk of serious adverse events in older patients with stages II-IIIA non-small cell lung cancer treated with or without postoperative platinum based chemotherapy. Design: Observational cohort study. Setting: Cases of lung cancer in Surveillance Epidemiology and End Results registry linked to Medicare files, 1992-2005, and follow-up data to December 2007. Participants: 3324 patients aged more than 65 years with resected stages II-IIIA lung cancer. Main outcome measures: Primary outcome was overall survival and secondary outcome was the rate of serious adverse events among older patients treated with or without adjuvant chemotherapy. Results: Overall, 21% (n=684) of patients received platinum based chemotherapy. Analyses adjusted, stratified, or matched by propensity scores showed that chemotherapy was associated with improved survival (hazard ratio range 0.78-0.81). The beneficial effect of chemotherapy was also observed among patients treated with radiation therapy (0.75-0.77) or without radiation therapy (0.74-0.77); however, chemotherapy was not beneficial for patients aged 80 or more (1.32-1.46). Adjuvant chemotherapy was associated with an increased odds of serious adverse events (odds ratio 2.0, 95% confidence interval 1.5 to 2.6). Conclusions: Platinum based adjuvant chemotherapy is associated with reduced mortality and increased risk of serious adverse events in older patients with stages II-IIIA lung cancer. The magnitude of the benefit is similar to that observed in randomised controlled trials carried out among selected patients.

Original languageEnglish (US)
Article numberd4013
JournalBMJ (Online)
Volume343
Issue number7817
DOIs
StatePublished - Jul 30 2011
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Observational Studies
Lung Neoplasms
Cohort Studies
Survival
Drug Therapy
Platinum
Radiotherapy
Propensity Score
Medicare
Non-Small Cell Lung Carcinoma
Registries
Epidemiology
Randomized Controlled Trials
Odds Ratio
Outcome Assessment (Health Care)
Confidence Intervals
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer : Observational cohort study. / Wisnivesky, Juan P.; Smith, Cardinale B.; Packer, Stuart; Strauss, Gary M.; Lurslurchachai, Linda; Federman, Alex; Halm, Ethan A.

In: BMJ (Online), Vol. 343, No. 7817, d4013, 30.07.2011.

Research output: Contribution to journalArticle

Wisnivesky, Juan P. ; Smith, Cardinale B. ; Packer, Stuart ; Strauss, Gary M. ; Lurslurchachai, Linda ; Federman, Alex ; Halm, Ethan A. / Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer : Observational cohort study. In: BMJ (Online). 2011 ; Vol. 343, No. 7817.
@article{5df904f17f8a427f8fde45024d06b7c2,
title = "Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: Observational cohort study",
abstract = "Objective: To compare the survival and risk of serious adverse events in older patients with stages II-IIIA non-small cell lung cancer treated with or without postoperative platinum based chemotherapy. Design: Observational cohort study. Setting: Cases of lung cancer in Surveillance Epidemiology and End Results registry linked to Medicare files, 1992-2005, and follow-up data to December 2007. Participants: 3324 patients aged more than 65 years with resected stages II-IIIA lung cancer. Main outcome measures: Primary outcome was overall survival and secondary outcome was the rate of serious adverse events among older patients treated with or without adjuvant chemotherapy. Results: Overall, 21{\%} (n=684) of patients received platinum based chemotherapy. Analyses adjusted, stratified, or matched by propensity scores showed that chemotherapy was associated with improved survival (hazard ratio range 0.78-0.81). The beneficial effect of chemotherapy was also observed among patients treated with radiation therapy (0.75-0.77) or without radiation therapy (0.74-0.77); however, chemotherapy was not beneficial for patients aged 80 or more (1.32-1.46). Adjuvant chemotherapy was associated with an increased odds of serious adverse events (odds ratio 2.0, 95{\%} confidence interval 1.5 to 2.6). Conclusions: Platinum based adjuvant chemotherapy is associated with reduced mortality and increased risk of serious adverse events in older patients with stages II-IIIA lung cancer. The magnitude of the benefit is similar to that observed in randomised controlled trials carried out among selected patients.",
author = "Wisnivesky, {Juan P.} and Smith, {Cardinale B.} and Stuart Packer and Strauss, {Gary M.} and Linda Lurslurchachai and Alex Federman and Halm, {Ethan A.}",
year = "2011",
month = "7",
day = "30",
doi = "10.1136/bmj.d4013",
language = "English (US)",
volume = "343",
journal = "BMJ (Online)",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "7817",

}

TY - JOUR

T1 - Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer

T2 - Observational cohort study

AU - Wisnivesky, Juan P.

AU - Smith, Cardinale B.

AU - Packer, Stuart

AU - Strauss, Gary M.

AU - Lurslurchachai, Linda

AU - Federman, Alex

AU - Halm, Ethan A.

PY - 2011/7/30

Y1 - 2011/7/30

N2 - Objective: To compare the survival and risk of serious adverse events in older patients with stages II-IIIA non-small cell lung cancer treated with or without postoperative platinum based chemotherapy. Design: Observational cohort study. Setting: Cases of lung cancer in Surveillance Epidemiology and End Results registry linked to Medicare files, 1992-2005, and follow-up data to December 2007. Participants: 3324 patients aged more than 65 years with resected stages II-IIIA lung cancer. Main outcome measures: Primary outcome was overall survival and secondary outcome was the rate of serious adverse events among older patients treated with or without adjuvant chemotherapy. Results: Overall, 21% (n=684) of patients received platinum based chemotherapy. Analyses adjusted, stratified, or matched by propensity scores showed that chemotherapy was associated with improved survival (hazard ratio range 0.78-0.81). The beneficial effect of chemotherapy was also observed among patients treated with radiation therapy (0.75-0.77) or without radiation therapy (0.74-0.77); however, chemotherapy was not beneficial for patients aged 80 or more (1.32-1.46). Adjuvant chemotherapy was associated with an increased odds of serious adverse events (odds ratio 2.0, 95% confidence interval 1.5 to 2.6). Conclusions: Platinum based adjuvant chemotherapy is associated with reduced mortality and increased risk of serious adverse events in older patients with stages II-IIIA lung cancer. The magnitude of the benefit is similar to that observed in randomised controlled trials carried out among selected patients.

AB - Objective: To compare the survival and risk of serious adverse events in older patients with stages II-IIIA non-small cell lung cancer treated with or without postoperative platinum based chemotherapy. Design: Observational cohort study. Setting: Cases of lung cancer in Surveillance Epidemiology and End Results registry linked to Medicare files, 1992-2005, and follow-up data to December 2007. Participants: 3324 patients aged more than 65 years with resected stages II-IIIA lung cancer. Main outcome measures: Primary outcome was overall survival and secondary outcome was the rate of serious adverse events among older patients treated with or without adjuvant chemotherapy. Results: Overall, 21% (n=684) of patients received platinum based chemotherapy. Analyses adjusted, stratified, or matched by propensity scores showed that chemotherapy was associated with improved survival (hazard ratio range 0.78-0.81). The beneficial effect of chemotherapy was also observed among patients treated with radiation therapy (0.75-0.77) or without radiation therapy (0.74-0.77); however, chemotherapy was not beneficial for patients aged 80 or more (1.32-1.46). Adjuvant chemotherapy was associated with an increased odds of serious adverse events (odds ratio 2.0, 95% confidence interval 1.5 to 2.6). Conclusions: Platinum based adjuvant chemotherapy is associated with reduced mortality and increased risk of serious adverse events in older patients with stages II-IIIA lung cancer. The magnitude of the benefit is similar to that observed in randomised controlled trials carried out among selected patients.

UR - http://www.scopus.com/inward/record.url?scp=84859005517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859005517&partnerID=8YFLogxK

U2 - 10.1136/bmj.d4013

DO - 10.1136/bmj.d4013

M3 - Article

VL - 343

JO - BMJ (Online)

JF - BMJ (Online)

SN - 0959-8146

IS - 7817

M1 - d4013

ER -